JUN 1 0 2004

TEM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : RUDOLF, K. et al U.S. Appln. No. : 10/687,262 Confirmation No. : 9943 U.S. Filing Date : October 16, 2003 Title of Invention : Selected CGRP antagonic as pharmaceutical composi Attny. Docket No. : 1/1402		1625 To be assigned eparing them and their use
Mail Stop Amendments Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
June 8, 2004		
TRANSMITTAL LETTER FOR INFO	RMATION DISCL	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject a Statement (Form 1449A/B) under 37 C.F.R. § hereinbelow.		
1.97(b). This Statement is being date of a national application other than a cons§1.53 (d); ii) within three (3) months of the da 37 C.F.R. §1.491 in an international application the merits; or iv) before the mailing of a fin continued examination under 37 C.F.R. §1.11	tinued prosecution a te of entry of the na on; iii) before the ma est Office action after	ttional stage as set forth in ailing of a first Office action
1.97(c). This Statement is being C.F.R. §1.97(b), but before the mailing date o notice of allowance under 37 C.F.R. §1.311, on the application. This Statement is being account to the statement is account to the statement is being account to the statement is account to t	f: i) a final action un or iii) an action that	nder 37 C.F.R. §1.113, ii) a
A statement as specified in 37	C.F.R. §1.97(e) [se	e below]; or
The fee set forth in 37 C.F.R. §	1.17(p).	

The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4868 Date: June 8, 2004 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendments Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on June 8, 200%

Alan R. Stempel, Reg. No. 78,99

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/687,262 Filing Date October 16, 2003 INFORMATION DISCLOSURE First Named Inventor RUDOLF, K. et al STATEMENT BY APPLICANT Art Unit 1625

Examiner Name To be assigned (Use as many sheets as necessary, Attorney Docket Number | 1/1402

			U. S. PATENT	DOCUMENTS .	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,521,609 B1	02/18/2003	Henri Doods et al	
		US-			
	 	US-			
		US-			
		US-			
***************************************		US-			
		US-			
		US-			
		US-			
	 	US-			
***************************************		US-			
	l	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 01/10425 A2	02/15/2001	Boehringer Ingelheim Pharma		
	1	WO 00/18764	04/06/2000	Merck Sharp & Dohme Limited		
***************************************	1					
***************************************	1					

Examiner	Date	
Signature	Considered	
J.g		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN 1 0 2004

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/687,262 Filing Date INFORMATION DISCLOSURE October 16, 2003 First Named Inventor STATEMENT BY APPLICANT RUDOLF, K. et al Art Unit 1625 (Use as many sheets as necessary) Examiner Name To be assigned Sheet of Attorney Docket Number 1/1402 2 2

	NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		JOHN J. MALLEE ET AL; Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonists; The Journal of Biological Chemistry (4-19-2002) Vol. 277 No. 16 page 14294-14928; The American Society for Biochemistry and Molecular Biology, Inc.	

			•••••

	»		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.